Edgewise Therapeutics Inc [EWTX] stock is trading at $14.15, up 1.58%. An important factor to consider is whether the stock is rising or falling in short-term value. The EWTX shares have gain 11.59% over the last week, with a monthly amount glided 3.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on July 30, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $46. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 30, 2025, and set its price target to $42. On April 30, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $41 on the stock. Scotiabank downgraded its rating to a Sector Perform but stick to its price target of $14 on April 02, 2025. Scotiabank initiated its recommendation with a Sector Outperform and recommended $50 as its price target on March 07, 2025. Stifel started tracking with a Hold rating for this stock on January 22, 2025, and assigned it a price target of $30. In a note dated November 22, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $45 on this stock.
Edgewise Therapeutics Inc [EWTX] stock has fluctuated between $10.60 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $14.15 at the most recent close of the market. An investor can expect a potential return of 253.36% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
Gross Profit Margin for this corporation currently stands at -1.11% with Operating Profit Margin at -82.41%, Pretax Profit Margin comes in at -71.15%, and Net Profit Margin reading is -71.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.31 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.93 points at the first support level, and at 13.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.27, and for the 2nd resistance point, it is at 14.38.
Ratios To Look Out For
For context, Edgewise Therapeutics Inc’s Current Ratio is 28.87. On the other hand, the Quick Ratio is 28.87, and the Cash Ratio is 2.08.
Transactions by insiders
Recent insider trading involved MOORE JOHN R, General Counsel, that happened on Aug 12 ’25 when 2098.0 shares were sold. Chief Business Officer, Derakhshan Behrad completed a deal on Aug 12 ’25 to sell 2491.0 shares. Meanwhile, Chief Financial Officer Carruthers R Michael sold 1428.0 shares on Aug 12 ’25.
